Apple Hui Min Tay, Rubén Prieto-Díaz, Shiyong Neo, Le Tong, Xinsong Chen, Valentina Carannante, Björn Önfelt, Johan Hartman, Felix Haglund, Maria Majellaro, Jhonny Azuaje, Xerardo Garcia-Mera, Jose M Brea, Maria I Loza, Willem Jespers, Hugo Gutierrez-de-Teran, Eddy Sotelo, Andreas Lundqvist
BACKGROUND: Adenosine is a metabolite that suppresses antitumor immune response of T and NK cells via extracellular binding to the two subtypes of adenosine-2 receptors, A2 ARs. While blockade of the A2A ARs subtype effectively rescues lymphocyte activity, with four A2A AR antagonists currently in anticancer clinical trials, less is known for the therapeutic potential of the other A2B AR blockade within cancer immunotherapy. Recent studies suggest the formation of A2A AR/A2B AR dimers in tissues that coexpress the two receptor subtypes, where the A2B AR plays a dominant role, suggesting it as a promising target for cancer immunotherapy...
May 2022: Journal for Immunotherapy of Cancer